MS Frontiers 2022 | ChariotMS: the first DMT trial in advanced multiple sclerosis
Klaus Schmierer, MB BS, PhD, FRCP, Queen Mary University of London & The Royal London Hospital of Barts Health NHS Trust, London, UK, outlines the details of the upcoming ChariotMS trial, looking at the treatment of patients with multiple sclerosis (MS) with an EDSS of 6.5-8. At this stage of disease, patients are normally confined to wheelchairs or can only walk short distances and there are no disease-modifying therapies (DMTs) available in this setting. Additionally, this patient population is often excluded from clinical trials, as walking ability is often used as a key measure of treatment efficacy. With no upper age limit, ChariotMS is the first disease-modifying drug trial focused on advanced MS. The trial will test cladribine and the primary efficacy outcome will be the maintenance of upper limb function. This interview took place at the MS Frontiers 2022 congress in Swansea, UK.
Disclosures
KS has received research support from Biogen, the healthcare business of Merck KGaA (Darmstadt, Germany), and Novartis; speaking honoraria from, and/or served in an advisory role for, Amgen- Gensenta, Biogen, EMD Serono, the healthcare business of Merck KGaA (Darmstadt, Germany), Novartis, Roche, Sanofi, and Teva; and remuneration for teaching activities from AcadeMe, Medscape, and the Neurology Academy.
